Market closed
Atara Biotherapeutics/$ATRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Atara Biotherapeutics
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Ticker
$ATRA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
153
Website
ATRA Metrics
BasicAdvanced
$39M
-
-$11.41
0.49
-
Price and volume
Market cap
$39M
Beta
0.49
52-week high
$20.81
52-week low
$5.40
Average daily volume
77K
Financial strength
Current ratio
0.482
Quick ratio
0.327
Long term debt to equity
-32.395
Total debt to equity
-46.701
Interest coverage (TTM)
-16.97%
Management effectiveness
Return on assets (TTM)
-35.66%
Return on equity (TTM)
86.92%
Valuation
Price to revenue (TTM)
0.391
Price to book
-0.41
Price to tangible book (TTM)
-0.41
Price to free cash flow (TTM)
-0.732
Growth
Revenue change (TTM)
1,404.02%
Earnings per share change (TTM)
-82.50%
3-year revenue growth (CAGR)
85.07%
3-year earnings per share growth (CAGR)
-49.92%
What the Analysts think about ATRA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Atara Biotherapeutics stock.
ATRA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ATRA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ATRA News
AllArticlesVideos
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
Business Wire·2 weeks ago
The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation
Accesswire·3 weeks ago
The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation
Accesswire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Atara Biotherapeutics stock?
Atara Biotherapeutics (ATRA) has a market cap of $39M as of March 22, 2025.
What is the P/E ratio for Atara Biotherapeutics stock?
The price to earnings (P/E) ratio for Atara Biotherapeutics (ATRA) stock is 0 as of March 22, 2025.
Does Atara Biotherapeutics stock pay dividends?
No, Atara Biotherapeutics (ATRA) stock does not pay dividends to its shareholders as of March 22, 2025.
When is the next Atara Biotherapeutics dividend payment date?
Atara Biotherapeutics (ATRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Atara Biotherapeutics?
Atara Biotherapeutics (ATRA) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.